Evidence map›Paper›PMID 35993739›Full record

ArticleJournal of virology2022

Role of VP30 Phosphorylation in Ebola Virus Nucleocapsid Assembly and Transport.

Yuki Takamatsu, Tomoki Yoshikawa, Takeshi Kurosu, Shuetsu Fukushi, Noriyo Nagata, Masayuki Shimojima, Hideki Ebihara, Masayuki Saijo, Takeshi Noda

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yuki TakamatsuLaboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto Universitygrid.258799.8, Kyoto, Japan.
Tomoki YoshikawaDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Takeshi KurosuDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Shuetsu FukushiDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Noriyo NagataDepartment of Pathology, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.ORCID 0000-0001-9147-1438
Masayuki ShimojimaDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Hideki EbiharaDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Masayuki SaijoDepartment of Virology I, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.ORCID 0000-0001-5458-7298
Takeshi NodaLaboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto Universitygrid.258799.8, Kyoto, Japan.ORCID 0000-0002-0658-4663
National Institute of Infectious Diseases · JPKyoto University · JPPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ebola virus (EBOV) VP30 regulates viral genome transcription and replication by switching its phosphorylation status. However, the importance of VP30 phosphorylation and dephosphorylation in other viral replication processes such as nucleocapsid and virion assembly is unclear. Interestingly, VP30 is predominantly dephosphorylated by cellular phosphatases in viral inclusions, while it is phosphorylated in the released virions. Thus, uncertainties regarding how VP30 phosphorylation in nucleocapsids is achieved and whether VP30 phosphorylation provides any advantages in later steps in viral replication have arisen. In the present study, to characterize the roles of VP30 phosphorylation in nucleocapsid formation, we used electron microscopic analyses and live cell imaging systems. We identified VP30 localized to the surface of protrusions surrounding nucleoprotein (NP)-forming helical structures in the nucleocapsid, suggesting the involvement in assembly and transport of nucleocapsids. Interestingly, VP30 phosphorylation facilitated its association with nucleocapsid-like structures (NCLSs). On the contrary, VP30 phosphorylation does not influence the transport characteristics and NCLS number leaving from and coming back into viral inclusions, indicating that the phosphorylation status of VP30 is not a prerequisite for NCLS departure. Moreover, the phosphorylation status of VP30 did not cause major differences in nucleocapsid transport in authentic EBOV-infected cells. In the following budding step, the association of VP30 and its phosphorylation status did not influence the budding efficiency of virus-like particles. Taken together, it is plausible that EBOV may utilize the phosphorylation of VP30 for its selective association with nucleocapsids, without affecting nucleocapsid transport and virion budding processes.

Indexed as

EbolavirusNucleocapsidTranscription FactorsViral ProteinsVirus AssemblyBiological TransportHemorrhagic Fever, EbolaHumansPhosphorylationVirionTranscription FactorsViral ProteinsVP30 protein, ebola virusassemblyEbola virusnucleocapsidnucleocapsid-like structurephosphorylationtransportVP30

Identifiers

PMID35993739
PMCPMC9472631
OpenAlexW4292608166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.